Skip to content

In the BioHarmony Drug Report Database

Tildrakizumab

Ilumya, Ilumetri (tildrakizumab) is an antibody pharmaceutical. Tildrakizumab was first approved as Ilumya on 2018-03-20. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-23 subunit alpha.
Trade Name Ilumetri
Common Name Tildrakizumab
Indication psoriasis
Drug Class Monoclonal antibodies: humanized, interleukins as target
Tildrakizumab
Get full access now